you are here: Home News Divis Lab

Divis Lab

Sai Life Sciences: Getting positioned for complex offerings
Divi’s Lab: Time to take some profit off the table?
Divi’s Lab: Better capex guidance to meet upcoming demand
Divi's Labs shares rise as HSBC raises rating to 'buy', ups target price
Divi's Labs shares rise 5% as Citi maintains 'BUY' rating, sees up to 19% upside
Divis Lab: GLP-1 opportunity to unfold in the medium term
Tata Motors, Asian Paints , Divis Laboratories, LIC & ITI | Stocks On Radar
Divi’s Lab: Custom synthesis business gaining ground
Brokerage Radar: Analysts bullish on Torrent Pharma; CLSA assigns 'outperform' rating to Power Grid, Sun TV
Live: Nifty gives up gains after coming close to record high | Nestle in focus | Closing Bell
Weekly Tactical Pick: A pharma stock set to ride emerging opportunities
Divi’s Lab: FY25 to witness sizeable improvement in performance
Emerging opportunities can help re-rate Divi’s lab
Weekly Tactical Pick: Divi’s Lab is better placed to ride the API up-cycle
Divi’s Lab: Emerging opportunities can re-invent the earnings wheel
Live: Nifty ends positive; Divis Lab among gainers, Britannia among losers | Bajar Gupshup
Robust growth in banks, NBFCs; engineering space sees strong order flow: Saurabh Mukherjea
Divi’s Lab: Sequential improvement, but long way to go
Gainers & Losers: 10 stocks that moved the most on April 12
Divi’s Labs: Focus on green chemistry
Divis Lab Q1 PAT seen up 27.3% YoY to Rs 709 cr: ICICI Direct
Divi’s Labs: Steady margin profile amid cost headwind
Aether IPO | This niche chemical player is a leader of the pack. How?
Indian chemical industry in a sweet spot as Europe struggles
Hikal: Green integrity in the spotlight, more than financials

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Divis Lab

Sai Life Sciences: Getting positioned for complex offerings

Divi’s Lab: Time to take some profit off the table?

Divi’s Lab: Better capex guidance to meet upcoming demand

Divi's Labs shares rise as HSBC raises rating to 'buy', ups target price

Divi's Labs shares rise 5% as Citi maintains 'BUY' rating, sees up to 19% upside

Divis Lab: GLP-1 opportunity to unfold in the medium term

Tata Motors, Asian Paints , Divis Laboratories, LIC & ITI | Stocks On Radar

Divi’s Lab: Custom synthesis business gaining ground

Brokerage Radar: Analysts bullish on Torrent Pharma; CLSA assigns 'outperform' rating to Power Grid, Sun TV

Live: Nifty gives up gains after coming close to record high | Nestle in focus | Closing Bell

Weekly Tactical Pick: A pharma stock set to ride emerging opportunities

Divi’s Lab: FY25 to witness sizeable improvement in performance

Emerging opportunities can help re-rate Divi’s lab

Weekly Tactical Pick: Divi’s Lab is better placed to ride the API up-cycle

Divi’s Lab: Emerging opportunities can re-invent the earnings wheel

Live: Nifty ends positive; Divis Lab among gainers, Britannia among losers | Bajar Gupshup

Robust growth in banks, NBFCs; engineering space sees strong order flow: Saurabh Mukherjea

Divi’s Lab: Sequential improvement, but long way to go

Gainers & Losers: 10 stocks that moved the most on April 12

Divi’s Labs: Focus on green chemistry

Divis Lab Q1 PAT seen up 27.3% YoY to Rs 709 cr: ICICI Direct

Divi’s Labs: Steady margin profile amid cost headwind

Aether IPO | This niche chemical player is a leader of the pack. How?

Indian chemical industry in a sweet spot as Europe struggles

Hikal: Green integrity in the spotlight, more than financials